Prospective Case-Control Study of Cardiovascular Changes in Pregnancy Related Hypertensive Disorders
Key facts
- Who runs it
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 12 people enrolled
- Started
- 1 Jul 2021
- Ended
- 17 Jan 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ARTSENS Pen
- Record updated
- 30 January 2024
- Why it stopped
- slow enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Other criteria
- Case Inclusion Criteria:
- Adult females age > 18 years
- Must be able to read and understand English and consent for themselves
- Must have a singleton pregnancy and a diagnosis of preeclampsia or gestational hypertension
- Must be willing and able to come to West Penn Hospital for post-partum visits at 6-8 weeks and then at 6-7 months; Case Exclusion Criteria:
- Prior history of hypertension
- Multiple pregnancies
- Other comorbidities such as congenital heart disease, dialysis dependent renal failure, heroin abuse, cocaine abuse, pulmonary hypertension, congestive heart failure, autoimmune conditions such as SLE or severe lung disease
- Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures; Control Inclusion Criteria:
- Adult females age > 18 years
- Must be able to read and understand English and consent for themselves
- Must have a singleton pregnancy and not have a prior or current diagnosis of hypertension
- Must be willing and able to come to West Penn Hospital for post-partum visits at 6-8 weeks; Control Exclusion Criteria:
- Prior history and/or current diagnosis of hypertension
- Multiple pregnancies
- Other comorbidities such as congenital heart disease, dialysis dependent renal failure, heroin abuse, cocaine abuse, pulmonary hypertension, congestive heart failure, autoimmune conditions such as SLE or severe lung disease
- Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Where in United States
- West Penn HospitalPittsburgh, United States
About the trial
What the trial wants to find out
This is a research study to understand the changes in the heart and the cardiovascular system that may occur in women who develop high blood pressure during pregnancy.
The 3 groups in the trial
- Pregnant with Pre-eclampsiaTreatment being tested
There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
Treatment: ARTSENS Pen
- Pregnant with gestational hypertensionTreatment being tested
There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
Treatment: ARTSENS Pen
- Pregnant without Hypertension - ControlExisting treatment, for comparison
There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.
Treatment: ARTSENS Pen
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 January 2024